These results indicate that SSTR2 blockade (Rossowski et al., 1998; Hocart et al., 1999) may be a novel treatment strategy of improving counterregulatory responses, including glucagon, to insulin-induced hypoglycemia. This evidence concerns the gene GCG and Hypoglycemia.